Genmab A (GMAB) Depreciation & Amortization (CF) (2024 - 2026)
Genmab A's (GMAB) quarterly Depreciation & Amortization (CF) came in at $16.0 million in Q1 2026, up 33.33% YoY from $12.0 million in Q1 2025, and down 58.97% on a QoQ basis from $39.0 million in Q3 2025.
Genmab A (GMAB) Depreciation & Amortization (CF) (2024 - 2026) Analysis & Trends
Genmab A (GMAB) has 3 years of Depreciation & Amortization (CF) data on file, last reported at $16.0 million in Q1 2026.
- Quarterly Depreciation & Amortization (CF) rose 33.33% year-over-year to $16.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $80.0 million (up 12.68% YoY) and the FY2025 annual result came in at $55.0 million, up 12.24% from the prior year.
- Depreciation & Amortization (CF) slipped to $16.0 million in Q1 2026, from $39.0 million in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $39.0 million in Q3 2025 to a low of $11.0 million in Q1 2024.
- A 3-year average of $23.1 million and a median of $23.0 million in 2024 frame the typical range for Depreciation & Amortization (CF).
- Annual changes were most pronounced in 2025 — Depreciation & Amortization (CF) grew 8.33% — and 2026, when it jumped 33.33%.
- Tracing GMAB's Depreciation & Amortization (CF) over 3 years: stood at $36.0 million in 2024, then climbed by 8.33% to $39.0 million in 2025, then slumped by 58.97% to $16.0 million in 2026.
- The last three Depreciation & Amortization (CF) figures came in at $16.0 million (Q1 2026), $39.0 million (Q3 2025), and $25.0 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.10 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 40.52 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 3.18 Mn |
| 10 | Genmab A | 2.05 Bn | 548.77 Mn | 1.07 Bn | 14.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 14.00 Mn |
| Jun 30, 2026 | 14.00 Mn |
| Mar 31, 2026 | 16.00 Mn |
| Mar 31, 2026 | 16.00 Mn |
| Sep 30, 2025 | 39.00 Mn |
| Sep 30, 2025 | 39.00 Mn |
| Jun 30, 2025 | 25.00 Mn |
| Jun 30, 2025 | 25.00 Mn |
| Mar 31, 2025 | 12.00 Mn |
| Mar 31, 2025 | 12.00 Mn |
| Sep 30, 2024 | 36.00 Mn |
| Sep 30, 2024 | 36.00 Mn |
| Jun 30, 2024 | 23.00 Mn |
| Jun 30, 2024 | 23.00 Mn |
| Mar 31, 2024 | 11.00 Mn |
| Mar 31, 2024 | 11.00 Mn |